Jasper Therapeutics is trading 12.33% down now at $0.61 after U.S.-Iran tensions lifted oil prices and pressured biotechnology shares.
- It fell 5.29% in after-hours trading on September 1, 2026.
- No new company-specific announcement appears on its investor-relations releases page for September 2, 2026; the latest listed releases concern the July 16 Kira merger and financing.
- The move is best attributed to global risk-off sentiment rather than a company catalyst.